Shree Ganesh Bio-Tech Reports Audited Standalone Financial Results for FY26
Shree Ganesh Bio-Tech (India) Limited reported audited standalone financial results for the year ended March 31, 2026, with net profit after tax rising to Rs. 37.76 lacs from Rs. 27.84 lacs, even as revenue from operations declined sharply to Rs. 497.05 lacs from Rs. 2,295.76 lacs. For Q4 FY26, the net loss narrowed significantly to Rs. (14.93) lacs compared to Rs. (94.60) lacs in Q4 FY25. Total assets stood at Rs. 6,380.29 lacs with no borrowings, and the statutory auditor issued an unmodified opinion on the financial statements.
*this image is generated using AI for illustrative purposes only.
Shree Ganesh Bio-Tech (India) Limited convened a Board of Directors meeting on May 14, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026, in accordance with Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 05:00 PM and concluded at 05:30 PM. The statutory auditor, Bipin & Co., Chartered Accountants (Firm Registration Number: 101509W), issued an unmodified opinion on the standalone financial statements for the financial year ended March 31, 2026. The audit was conducted by CA Amit Shah (Membership No.: 126337) from Vadodara, and the financial results were reviewed by the Audit Committee prior to Board approval.
Annual Financial Performance
For the full year ended March 31, 2026, Shree Ganesh Bio-Tech reported a net profit after tax of Rs. 37.76 lacs, compared to Rs. 27.84 lacs in the year ended March 31, 2025, reflecting year-on-year improvement in profitability. However, revenue from operations declined sharply to Rs. 497.05 lacs from Rs. 2,295.76 lacs in the prior year. Total income for the year stood at Rs. 644.27 lacs, against Rs. 2,439.85 lacs in the previous year. Total expenses reduced significantly to Rs. 592.86 lacs from Rs. 2,401.16 lacs. The following table presents the key annual financial metrics (figures in Rs. in lacs):
| Metric: | Year Ended 31-Mar-26 (Audited) | Year Ended 31-Mar-25 (Audited) |
|---|---|---|
| Revenue from Operations: | 497.05 | 2,295.76 |
| Other Income: | 147.22 | 144.09 |
| Total Income: | 644.27 | 2,439.85 |
| Cost of Materials Consumed: | 505.57 | 2,264.10 |
| Employee Benefit Expense: | 16.48 | 9.76 |
| Other Expenses: | 70.75 | 127.25 |
| Total Expenses: | 592.86 | 2,401.16 |
| Profit Before Tax: | 51.41 | 38.69 |
| Tax Expense: | 13.65 | 10.85 |
| Net Profit After Tax: | 37.76 | 27.84 |
| Basic EPS (Rs. 1/- each, not annualised): | 0.01 | 0.01 |
| Diluted EPS (Rs. 1/- each, not annualised): | 0.01 | 0.01 |
Quarterly Financial Performance
For the quarter ended March 31, 2026, the company recorded a net loss of Rs. (14.93) lacs, a marked improvement compared to a net loss of Rs. (94.60) lacs in the corresponding quarter ended March 31, 2025. Revenue from operations for the quarter stood at Rs. 212.13 lacs, against Rs. 300.57 lacs in the same period of the prior year. Total expenses for the quarter were Rs. 254.65 lacs, compared to Rs. 441.69 lacs in the year-ago quarter. The quarter ended December 31, 2025 had reported a net profit of Rs. 32.23 lacs on revenue from operations of Rs. 69.81 lacs. Basic and diluted EPS for the quarter ended March 31, 2026 stood at (0.00), compared to (0.02) in the quarter ended March 31, 2025.
| Metric: | Q4 FY26 (31-Mar-26, Audited) | Q3 FY26 (31-Dec-25, Unaudited) | Q4 FY25 (31-Mar-25, Audited) |
|---|---|---|---|
| Revenue from Operations: | 212.13 | 69.81 | 300.57 |
| Other Income: | 27.59 | 37.08 | 46.52 |
| Total Income: | 239.72 | 106.90 | 347.09 |
| Total Expenses: | 254.65 | 74.67 | 441.69 |
| Profit / (Loss) Before Tax: | (14.93) | 32.23 | (94.60) |
| Net Profit / (Loss) After Tax: | (14.93) | 32.23 | (94.60) |
| Basic EPS (Rs. 1/- each, not annualised): | (0.00) | 0.01 | (0.02) |
| Diluted EPS (Rs. 1/- each, not annualised): | (0.00) | 0.01 | (0.02) |
Balance Sheet Highlights
As at March 31, 2026, total assets stood at Rs. 6,380.29 lacs, marginally higher than Rs. 6,348.76 lacs as at March 31, 2025. Shareholders' funds increased to Rs. 6,363.34 lacs from Rs. 6,325.59 lacs, comprising equity share capital of Rs. 3,986.24 lacs and other equity of Rs. 2,377.10 lacs. Inventories rose significantly to Rs. 1,173.10 lacs from Rs. 288.99 lacs, while non-current loans declined to Rs. 4,274.88 lacs from Rs. 5,094.09 lacs. Non-current investments remained unchanged at Rs. 915.00 lacs. The company reported no borrowings, either current or non-current, as at March 31, 2026.
| Balance Sheet Item: | As at 31-Mar-26 (Rs. in Lakhs) | As at 31-Mar-25 (Rs. in Lakhs) |
|---|---|---|
| Total Assets: | 6,380.29 | 6,348.76 |
| Non-Current Assets: | 5,190.01 | 6,009.28 |
| Current Assets: | 1,190.28 | 339.47 |
| Shareholders' Funds: | 6,363.34 | 6,325.59 |
| Equity Share Capital: | 3,986.24 | 3,986.24 |
| Other Equity: | 2,377.10 | 2,339.35 |
| Investments (Non-Current): | 915.00 | 915.00 |
| Non-Current Loans: | 4,274.88 | 5,094.09 |
| Inventories: | 1,173.10 | 288.99 |
| Cash and Cash Equivalents: | 0.97 | 1.31 |
| Total Current Liabilities: | 16.95 | 23.17 |
Cash Flow Summary
The standalone statement of cash flows, prepared under the indirect method as per Ind AS-7, reflects net cash outflow from operating activities of Rs. (819.56) lacs for the year ended March 31, 2026, compared to Rs. (1,021.21) lacs in the prior year. The operating cash outflow was primarily driven by an increase in inventory of Rs. 884.11 lacs. Net cash inflow from investing activities was Rs. 819.22 lacs, primarily driven by a decrease in long-term loans and advances, against Rs. 979.72 lacs in the prior year. There were no cash flows from financing activities during the year. As a result, cash and cash equivalents declined from Rs. 1.31 lacs at the opening of the year to Rs. 0.97 lacs at the close.
| Cash Flow Item: | Year Ended 31-Mar-26 (Rs. in Lacs) | Year Ended 31-Mar-25 (Rs. in Lacs) |
|---|---|---|
| Profit Before Tax: | 51.41 | 38.69 |
| Operating Profit Before Working Capital Changes: | 51.47 | 38.74 |
| Net Cash Flow from Operating Activities: | (819.56) | (1,021.21) |
| Net Cash Flow from Investing Activities: | 819.22 | 979.72 |
| Net Cash Flow from Financing Activities: | - | - |
| Opening Cash and Cash Equivalents: | 1.31 | 42.80 |
| Closing Cash and Cash Equivalents: | 0.97 | 1.31 |
Auditor's Opinion and Compliance
The financial results were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on May 14, 2026. The statutory auditors, Bipin & Co., Chartered Accountants, conducted the audit in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and confirmed that the financial statements give a true and fair view in conformity with applicable Indian Accounting Standards. The results were submitted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates in a single business segment, and accordingly, no separate segment results have been disclosed. Previous period figures have been regrouped or rearranged wherever necessary.
Historical Stock Returns for Shree Ganesh Bio-Tech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.28% | -3.28% | -14.49% | -14.49% | -35.16% | -90.17% |
What strategic initiatives is Shree Ganesh Bio-Tech planning to reverse the ~78% decline in revenue from operations and restore volumes closer to FY25 levels?
Given the sharp build-up in inventories to Rs. 1,173 lacs alongside near-zero cash reserves, how does the company plan to manage liquidity and working capital in FY27 without any borrowing facilities?
As non-current loans declined significantly from Rs. 5,094 lacs to Rs. 4,274 lacs, what is the nature and recoverability timeline of these loans, and could further recoveries fund future operational expansion?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
